High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jung Won | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Nam, Ryoung Hee | - |
dc.contributor.author | Kim, Jung Mogg | - |
dc.contributor.author | Park, Jong Youn | - |
dc.contributor.author | Lee, Sun Min | - |
dc.contributor.author | Kim, Joo Sung | - |
dc.contributor.author | Lee, Dong Ho | - |
dc.contributor.author | Jung, Hyun Chae | - |
dc.date.accessioned | 2022-07-15T19:57:59Z | - |
dc.date.available | 2022-07-15T19:57:59Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155702 | - |
dc.description.abstract | Finafloxacin is a novel fluoroquinolone with improved antimicrobial efficacy, especially in an acidic environment. The efficacy of finafloxacin for the inhibition of Helicobacter pylori infection was compared with the efficacies of levofloxacin and moxifloxacin at neutral and acidic pH. The impacts of gyrA point mutation on the efficacy of those three fluoroquinolones were also investigated. A total of 128 clinical H. pylori strains were utilized. MICs of levofloxacin, moxifloxacin, and finafloxacin were determined at pH 5.0 and pH 7.0 by the agar dilution method. The impact of gyrA point mutations that are responsible for fluoroquinolone resistance was analyzed; the results showed 50 strains with an Asn-87 point mutation, 48 strains with an Asp-91 point mutation, and the remaining 30 strains with no gyrA mutations. The use of finafloxacin led to MIC values at pH 5.0 that were lower than the values seen at pH 7.0 for 112 strains (112/128, 87.5%), and this proportion was higher than that seen with moxifloxacin (21/128, 16.4%, P < 0.001). Finafloxacin also demonstrated a rate of susceptibility (MIC,< 1 mu g/ml) (37.5%, 48/128) at pH 5.0 that was higher than that seen with moxifloxacin (2.3%, 3/128) (P < 0.001). The trends were similar regardless of which of the Asn-87, Asp-91, and A2143 point mutations were present. In conclusion, the superior antimicrobial efficacy of finafloxacin against H. pylori in an acidic environment suggests the possible use of finafloxacin for treatment of H. pylori infection, as has been proposed by its developer, Merlion Pharma. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC MICROBIOLOGY | - |
dc.title | High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jung Mogg | - |
dc.identifier.doi | 10.1128/AAC.01467-15 | - |
dc.identifier.scopusid | 2-s2.0-84954508894 | - |
dc.identifier.wosid | 000368337300057 | - |
dc.identifier.bibliographicCitation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v.59, no.12, pp.7629 - 7636 | - |
dc.relation.isPartOf | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.citation.title | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.citation.volume | 59 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 7629 | - |
dc.citation.endPage | 7636 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | ANTIBIOTIC-RESISTANCE | - |
dc.subject.keywordPlus | ANTIMICROBIAL RESISTANCE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GYRA | - |
dc.subject.keywordPlus | ERADICATION | - |
dc.subject.keywordPlus | CLARITHROMYCIN | - |
dc.subject.keywordPlus | LEVOFLOXACIN | - |
dc.subject.keywordPlus | SITAFLOXACIN | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.